{"id":32909,"date":"2018-12-14T12:00:00","date_gmt":"2018-12-14T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/"},"modified":"2018-12-14T12:00:00","modified_gmt":"2018-12-14T12:00:00","slug":"quel-est-lavenir-du-traitement-de-la-rhinite-allergique","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/","title":{"rendered":"Quel est l&#8217;avenir du traitement de la rhinite allergique ?"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1511 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Masterclass ARIA Bruxelles 2018<\/h2>\n<p>Les experts estiment que l&#8217;avenir de la rhinite allergique (RA) consistera principalement \u00e0 identifier les diff\u00e9rents g\u00e9notypes et endotypes et \u00e0 les traiter en cons\u00e9quence. L&#8217;avenir de la RA peut \u00e9galement s&#8217;orienter vers une th\u00e9rapie combin\u00e9e, en particulier une th\u00e9rapie combin\u00e9e intranasale associant des corticost\u00e9ro\u00efdes nasaux et un antihistaminique nasal, qui s&#8217;est av\u00e9r\u00e9e significativement plus efficace que l&#8217;un ou l&#8217;autre utilis\u00e9 seul. Pour les patients qui ne r\u00e9pondent pas \u00e0 ces traitements, l&#8217;immunoth\u00e9rapie allerg\u00e9nique pourrait constituer une voie prometteuse. Il peut \u00eatre important de mener des essais portant sur une immunoth\u00e9rapie allerg\u00e9nique plus pr\u00e9coce afin de d\u00e9terminer si elle peut pr\u00e9venir la progression de la maladie, notamment la progression vers l&#8217;asthme.   <\/p>\n<p>Ces entretiens avec le Pr Joaquim Mullol (Espagne) et le Pr Glenis Scadding (Royaume-Uni) ont \u00e9t\u00e9 enregistr\u00e9s lors de la masterclass ARIA du 12 septembre 2018 \u00e0 Bruxelles, Belgique.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1512 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"Lecteur vid\u00e9o YouTube\" src=\"https:\/\/www.youtube.com\/embed\/UKBo4fk20Cc?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Masterclass ARIA Bruxelles 2018 Les experts estiment que l&#8217;avenir de la rhinite allergique (RA) consistera principalement \u00e0 identifier les diff\u00e9rents g\u00e9notypes et endotypes et \u00e0 les traiter en cons\u00e9quence. L&#8217;avenir de la RA peut \u00e9galement s&#8217;orienter vers une th\u00e9rapie combin\u00e9e, en particulier une th\u00e9rapie combin\u00e9e intranasale associant des corticost\u00e9ro\u00efdes nasaux et un antihistaminique nasal, qui s&#8217;est av\u00e9r\u00e9e significativement plus efficace que l&#8217;un ou l&#8217;autre utilis\u00e9 seul. Pour les patients qui ne r\u00e9pondent pas \u00e0 ces traitements, l&#8217;immunoth\u00e9rapie allerg\u00e9nique pourrait constituer une voie prometteuse. Il peut \u00eatre important de mener des essais portant sur une immunoth\u00e9rapie allerg\u00e9nique plus pr\u00e9coce afin de d\u00e9terminer si elle peut pr\u00e9venir la progression de la maladie, notamment la progression vers l&#8217;asthme. Ces entretiens avec le Pr Joaquim Mullol (Espagne) et le Pr Glenis Scadding (Royaume-Uni) ont \u00e9t\u00e9 enregistr\u00e9s lors de la masterclass ARIA du 12 septembre 2018 \u00e0 Bruxelles, Belgique.<\/p>\n","protected":false},"author":1,"featured_media":32915,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[245],"tags":[172,180,216,248,269],"class_list":["post-32909","news","type-news","status-publish","has-post-thumbnail","hentry","category-professionnels-de-sante","tag-asthme","tag-evenements","tag-rhinoplastie","tag-immunotherapie-allergenique-ita","tag-rhinite-allergique-ra"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Quel est l&#039;avenir du traitement de la rhinite allergique ? - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quel est l&#039;avenir du traitement de la rhinite allergique ?\" \/>\n<meta property=\"og:description\" content=\"Masterclass ARIA Bruxelles 2018 Les experts estiment que l&#8217;avenir de la rhinite allergique (RA) consistera principalement \u00e0 identifier les diff\u00e9rents g\u00e9notypes et endotypes et \u00e0 les traiter en cons\u00e9quence. L&#8217;avenir de la RA peut \u00e9galement s&#8217;orienter vers une th\u00e9rapie combin\u00e9e, en particulier une th\u00e9rapie combin\u00e9e intranasale associant des corticost\u00e9ro\u00efdes nasaux et un antihistaminique nasal, qui s&#8217;est av\u00e9r\u00e9e significativement plus efficace que l&#8217;un ou l&#8217;autre utilis\u00e9 seul. Pour les patients qui ne r\u00e9pondent pas \u00e0 ces traitements, l&#8217;immunoth\u00e9rapie allerg\u00e9nique pourrait constituer une voie prometteuse. Il peut \u00eatre important de mener des essais portant sur une immunoth\u00e9rapie allerg\u00e9nique plus pr\u00e9coce afin de d\u00e9terminer si elle peut pr\u00e9venir la progression de la maladie, notamment la progression vers l&#8217;asthme. Ces entretiens avec le Pr Joaquim Mullol (Espagne) et le Pr Glenis Scadding (Royaume-Uni) ont \u00e9t\u00e9 enregistr\u00e9s lors de la masterclass ARIA du 12 septembre 2018 \u00e0 Bruxelles, Belgique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/\",\"name\":\"Quel est l'avenir du traitement de la rhinite allergique ? - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png\",\"datePublished\":\"2018-12-14T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png\",\"width\":1279,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Quel est l&#8217;avenir du traitement de la rhinite allergique ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Quel est l'avenir du traitement de la rhinite allergique ? - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/","og_locale":"fr_FR","og_type":"article","og_title":"Quel est l'avenir du traitement de la rhinite allergique ?","og_description":"Masterclass ARIA Bruxelles 2018 Les experts estiment que l&#8217;avenir de la rhinite allergique (RA) consistera principalement \u00e0 identifier les diff\u00e9rents g\u00e9notypes et endotypes et \u00e0 les traiter en cons\u00e9quence. L&#8217;avenir de la RA peut \u00e9galement s&#8217;orienter vers une th\u00e9rapie combin\u00e9e, en particulier une th\u00e9rapie combin\u00e9e intranasale associant des corticost\u00e9ro\u00efdes nasaux et un antihistaminique nasal, qui s&#8217;est av\u00e9r\u00e9e significativement plus efficace que l&#8217;un ou l&#8217;autre utilis\u00e9 seul. Pour les patients qui ne r\u00e9pondent pas \u00e0 ces traitements, l&#8217;immunoth\u00e9rapie allerg\u00e9nique pourrait constituer une voie prometteuse. Il peut \u00eatre important de mener des essais portant sur une immunoth\u00e9rapie allerg\u00e9nique plus pr\u00e9coce afin de d\u00e9terminer si elle peut pr\u00e9venir la progression de la maladie, notamment la progression vers l&#8217;asthme. Ces entretiens avec le Pr Joaquim Mullol (Espagne) et le Pr Glenis Scadding (Royaume-Uni) ont \u00e9t\u00e9 enregistr\u00e9s lors de la masterclass ARIA du 12 septembre 2018 \u00e0 Bruxelles, Belgique.","og_url":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/","url":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/","name":"Quel est l'avenir du traitement de la rhinite allergique ? - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png","datePublished":"2018-12-14T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/What20is20the20future20of20allergic20rhinitis20treatment3F-1.png","width":1279,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/fr\/news\/quel-est-lavenir-du-traitement-de-la-rhinite-allergique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/fr\/news\/"},{"@type":"ListItem","position":3,"name":"Quel est l&#8217;avenir du traitement de la rhinite allergique ?"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/fr\/#website","url":"https:\/\/www.euforea.org\/fr\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/fr\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/32909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=32909"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/32909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/32915"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=32909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=32909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=32909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}